Gemtuzumab ozogamicin in infants with AML: Results from the Children’s Oncology Group trials AAML03P1 and AAML0531

Erin M. Guest, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Todd A. Alonzo, Robert B. Gerbing, Yi Cheng Jim Wang, Samir B. Kahwash, Amy Heerema-McKenney, Soheil Meshinchi, Alan S. Gamis

Research output: Contribution to journalLetterpeer-review

8 Scopus citations
Original languageEnglish (US)
Pages (from-to)943-945
Number of pages3
JournalBlood
Volume130
Issue number7
DOIs
StatePublished - Aug 17 2017

Bibliographical note

Funding Information:
Acknowledgments: This study was supported by research funding from the National Institutes of Health, National Cancer Institute under award numbers U10CA180899 (T.A.A., R.B.G., and Y.-C.J.W.), U10CA180886 (R.A., L.S., S.C.R., B.A.H., S.B.K., A.H.-M., S.M., and A.S.G.), and U10CA098543 (R.A., L.S., S.C.R., B.A.H., S.B.K., A.H.-M., S.M., and A.S.G.), and the Andrew McDonough B+ Foundation (Y.-C.J.W.).

Cite this